P
087010
vs
K
KOSPI 200
Over the past 12 months, Peptron Inc has underperformed KOSPI 200, delivering a return of -36% compared to KOSPI 200's +152% growth.
Stocks Performance
087010 vs KOSPI 200
Performance Gap
087010 vs KOSPI 200
Performance By Year
087010 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Peptron Inc
Glance View
Peptron Inc. is a South Korean biotech company that develops long-acting drug formulations, especially injectable medicines built from peptides and other difficult-to-deliver molecules. Its main job is to take active drug ingredients and turn them into products that stay in the body longer and can be dosed less often, which can make treatment easier for patients and doctors. The company sells two main things: its own drug development programs and formulation know-how that can be used by pharmaceutical partners. In practice, it earns money through research and development collaborations, technology transfer, licensing, and product development work tied to specific drug candidates. Its customers are mostly drug makers and biotech companies that need help turning promising molecules into usable medicines. What makes Peptron different is its role in the drug value chain. It is not a mass-market drug seller; it sits upstream, where chemistry and delivery design matter most. That gives it a niche business model built around technical expertise, partnerships, and specialized formulations rather than broad branded drug sales.
